Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 February 2021 | Story André Damons | Photo Charl Devenish
Prof Mamello Sekhoacha, Associate Professor from the Department of Pharmacology in the Faculty of Health Sciences, was appointed by Dr Zweli Mkhize, Minister of Health, as the new chairperson of the National Health Research Ethics Council of South Africa (NHREC).

A researcher in the field of drug discovery and development at the University of the Free State (UFS) has been appointed by Dr Zweli Mkhize, Minister of Health, as the new chairperson of the National Health Research Ethics Council of South Africa (NHREC).

Prof Mamello Sekhoacha, Associate Professor from the Department of Pharmacology in the Faculty of Health Sciences, was appointed as a member of the NHREC council in 2013, and later became the chairperson of the NHREC’s Norms and Standards Committee responsible for developing and revising guidelines for health research. Prof Sekhoacha was appointed deputy chairperson of the council in 2018 and has played an integral part in setting ethical standards for conducting health research in the country.

 Responsibilities of the NHREC

The NHREC is the national statutory body responsible for the governance and advancement of health research ethics in South Africa. Some of the responsibilities of the council are to set ethical norms and standards for health research by developing and revising the guidelines pertaining to health research; to promote and monitor compliance with existing regulations by health research ethics committees; and to build capacity in research ethics committees through robust registration and audit processes.

These responsibilities of the NHREC rest on the need to ensure ethical integrity in research involving human participants and animal subjects, and that research is based on sound scientific and ethical principles.

“It is an honour for me to serve on the NHREC for the third term. The NHREC has achieved remarkable outputs over the past three years, and I believe, given the current composition of the council members, this momentum will not be lost. One of the goals of the NHREC is to further broaden the scope of the ethics in health research guidelines from ‘biomedical research’ to ‘health-related research’ to ensure that adequate guidance is provided for those in health-related disciplines, as a response to the changing environment of research involving humans and the broader meaning of health research.” 

“We need more comprehensive guidelines with nuanced commentaries to indicate how the ethical principles that emanated from biomedical research involving humans, could be effectively implemented in other disciplines of health-related research,” says Prof Sekhoacha. 

Global paradigm shift in role and integration of ethics in health research

Having been a council member since 2013, Prof Sekhoacha, whose training spans from pre-clinical laboratory experimentation, the use of animals in research, clinical trials, and working with indigenous communities, says there is a global paradigm shift in the role and integration of ethics in health research in almost all aspects of research, with an increased emphasis on the scientific and social value of research: the prospect of generating the knowledge in a manner that protects and promotes people's health. Considerations of the NHREC go beyond developing ethical guidelines or ensuring the efficient functioning of the ethics committees, to raising awareness among research institutions and researchers to continually promote ethically sound research conduct. 

The subject of ethics in health research is pivotal and reflective of the values of both the institution and the country at large. 

UFS uses Prof Sekhoacha’s expertise on ethics

Prof Sekhoacha is also a co-opted advisory member in the Senate Research Ethics Committee of the UFS and facilitates workshops and seminars on research ethics offered by the Postgraduate School.

Prof Corli Witthuhn, Vice-Rector: Research and Internationalisation, says it is a great honour for the UFS that Prof Sekhoacha has been elected chair of the NHREC.  “The NHREC governs the research ethics processes in South Africa, and it is strategically important for the UFS to now have one of our own academics play such a nationally important role.  We have been using Prof Sekhoacha’s expertise on issues of ethics and we are looking forward to working with her to continue to better our own ethics processes.”

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept